Datapoint: Roche Scores FDA Nod for New Eye Drug

The FDA last week approved Roche’s Vabysmo in neovascular (or “wet” age-related) macular degeneration and diabetic macular edema, eye disorders that are among the leading causes of blindness. The drug, which is the first FDA-approved bispecific antibody for the eye, will have to face off against Regeneron’s blockbuster Eylea. For the treatment of neovascular macular degeneration, Eylea holds covered or better status for 57% of all insured lives under the pharmacy benefit. Eylea is not covered for 30% of lives.

SOURCE: MMIT Analytics, as of 2/2/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 26

Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 25

Datapoint: Ohio Counties Offer the Most Medicare Advantage Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today